As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

PFS came in at 61.6% overall, at 62.9% in those with stable brain metastases, and at 59.6% in those with active brain ...

Enhertu has shown 'unprecedented' trial results, giving hope to mums like Maggie Ngatai.

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

The data as well as the results in patients without brain metastases further build confidence in the clinical profile of ENHERTU for the second-line treatment of HER2-positive metastatic breast cancer ...

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

New Zealand women with an aggressive form of incurable breast cancer will be given a better chance to spend more precious time with their loved ones, now that Pharmac has announced it intends to fund ...

Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu ...